- In December 2024, Novo Nordisk announced that its Alhemo (concizumab-mtci) injection received approval from the U.S. Food and Drug Administration (FDA). This approval is for a once-daily subcutaneous prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with inhibitors. This strengthens Novo Nordisk's portfolio and further its commitment to offering solutions for rare bleeding disorders, highlighting innovation beyond traditional anticoagulants
- In October 2024, Pfizer Inc. announced that it had received U.S. FDA approval for its HYMPAVZI (marstacimab-hncq). This is a once-weekly subcutaneous prophylactic treatment developed for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B without inhibitors, showcasing advancements in long-acting and patient-friendly treatments for bleeding disorders often related to anticoagulation
- In February 2024, Roche (F. Hoffmann-La Roche Ltd) launched three new coagulation tests for the oral Factor Xa inhibitors apixaban, edoxaban, and rivaroxaban in countries recognizing the CE mark. These tests are designed to facilitate clinical decision-making for prescribing direct oral anticoagulants (DOACs), primarily for stroke prevention, indicating an ongoing focus on improving the precision and safety of anticoagulant therapy
- In November 2023, Pharmascience Canada announced the launch of the generic drug (Pr) pms-RIVAROXABAN. This medicine, a direct Factor Xa inhibitor, belongs to the anticoagulant (blood thinner) group and helps prevent blood clots. The introduction of generic versions of NOACs contributes to increased accessibility and affordability of these crucial medications in Canada
- In July 2023, Endo International plc. launched bivalirudin injection in ready-to-use (RTU) vials in the U.S., in collaboration with Gland Pharma Limited, India, and MAIA Pharmaceuticals, Inc. The new RTU vials of bivalirudin are expected to offer more convenience and efficiency for healthcare professionals in acute care settings, enhancing the ease of administration for specific anticoagulant drugs
